SG10201705698PA - Aberrant Cell-Restricted Immunoglobulins Provided With A Toxic Moiety - Google Patents
Aberrant Cell-Restricted Immunoglobulins Provided With A Toxic MoietyInfo
- Publication number
- SG10201705698PA SG10201705698PA SG10201705698PA SG10201705698PA SG10201705698PA SG 10201705698P A SG10201705698P A SG 10201705698PA SG 10201705698P A SG10201705698P A SG 10201705698PA SG 10201705698P A SG10201705698P A SG 10201705698PA SG 10201705698P A SG10201705698P A SG 10201705698PA
- Authority
- SG
- Singapore
- Prior art keywords
- restricted
- aberrant cell
- toxic moiety
- immunoglobulins provided
- immunoglobulins
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Pregnancy & Childbirth (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gynecology & Obstetrics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261586568P | 2012-01-13 | 2012-01-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201705698PA true SG10201705698PA (en) | 2017-08-30 |
Family
ID=47682044
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201705698PA SG10201705698PA (en) | 2012-01-13 | 2013-01-11 | Aberrant Cell-Restricted Immunoglobulins Provided With A Toxic Moiety |
SG11201404007WA SG11201404007WA (en) | 2012-01-13 | 2013-01-11 | Aberrant cell-restricted immunoglobulins provided with a toxic moiety |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201404007WA SG11201404007WA (en) | 2012-01-13 | 2013-01-11 | Aberrant cell-restricted immunoglobulins provided with a toxic moiety |
Country Status (8)
Country | Link |
---|---|
US (5) | US20130183307A1 (en) |
EP (2) | EP2802356A1 (en) |
JP (3) | JP2015504895A (en) |
AU (2) | AU2013208364B2 (en) |
CA (1) | CA2860914A1 (en) |
SG (2) | SG10201705698PA (en) |
WO (1) | WO2013105856A1 (en) |
ZA (1) | ZA201405109B (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6177137B2 (en) * | 2010-12-27 | 2017-08-09 | エーピーオー‐ティー ビー.ヴイ. | Cross-linked polypeptides that induce apoptosis |
AU2012316859A1 (en) | 2011-09-29 | 2014-04-17 | Apo-T B.V. | Multi-specific binding molecules targeting aberrant cells |
WO2013105856A1 (en) | 2012-01-13 | 2013-07-18 | Apo-T B.V. | Aberrant cell-restricted immunoglobulins provided with a toxic moiety |
RU2609627C2 (en) * | 2014-09-26 | 2017-02-02 | Закрытое Акционерное Общество "Биокад" | High affinity and aggregationally stable antibodies based on vl variable domains and vhh derivative |
NL2014935B1 (en) * | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
EP3156067A1 (en) * | 2015-10-16 | 2017-04-19 | Max-Delbrück-Centrum Für Molekulare Medizin | High avidity hpv t-cell receptors |
CN107686522A (en) * | 2016-12-28 | 2018-02-13 | 天津天锐生物科技有限公司 | A kind of identification HLA A2/SLLMWITQC single domain antibody |
KR20200021074A (en) | 2017-06-14 | 2020-02-27 | 아디셋 바이오, 인크. | Antibodies capable of binding HLA-A2 / TYRD in a HLA restricted manner and uses thereof |
WO2019145792A1 (en) * | 2018-01-24 | 2019-08-01 | The Council Of The Queensland Institute Of Medical Research | Hpv immunotherapy |
JP2021528382A (en) | 2018-06-04 | 2021-10-21 | エーピーオー‐ティー ビー.ヴイ. | Methods and means of attracting immune effector cells to tumor cells |
NL2024375B1 (en) | 2019-12-04 | 2021-08-31 | Apo T B V | Methods and means for attracting immune effector cells to tumor cells. |
EP4110823A1 (en) * | 2020-02-26 | 2023-01-04 | A2 Biotherapeutics, Inc. | Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB601513A (en) | 1946-02-06 | 1948-05-06 | Koray Ltd | Improvements in or relating to coated tissue especially paper and to coating compositions therefor |
DE321017C (en) | 1917-05-15 | 1920-05-11 | Aloysius Petrus Van Leuven | |
US3687370A (en) | 1971-01-18 | 1972-08-29 | Instapak Corp | Liquid mixing and dispensing apparatus |
NL9001639A (en) * | 1990-07-19 | 1992-02-17 | Amc Amsterdam | PT-CONTAINING COMPOUND, METHOD FOR PREPARING IT, AND USE OF SUCH COMPOUNDS. |
US5709995A (en) | 1994-03-17 | 1998-01-20 | The Scripps Research Institute | Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses |
ES2205030T3 (en) * | 1995-05-09 | 2004-05-01 | Kreatech Biotechnology B.V. | PROCEDURES FOR THE PRODUCTION OF PLATINUM-BASED CONNECTION SEGMENTS BETWEEN BIO-ORGANIC MARKERS AND MOLECULES, FOR THE MARKING OF BIO-ORGANIC MOLECULES, THE DETECTION OF BIOLOGICAL SUBSTANCES TO BE STUDIED. |
WO1998045304A1 (en) | 1997-04-10 | 1998-10-15 | Kreatech Biotechnology B.V. | Trans-platinum compound, and diagnostic kit |
KR20010022812A (en) | 1997-08-12 | 2001-03-26 | 리드 비.브이. | Determining the transforming capability of agents |
WO1999042077A2 (en) | 1998-02-19 | 1999-08-26 | Xcyte Therapies, Inc. | Compositions and methods for regulating lymphocyte activation |
AU1218000A (en) | 1998-10-21 | 2000-05-08 | Sunol Molecular Corporation | Polyspecific binding molecules and uses thereof |
IL127142A0 (en) | 1998-11-19 | 1999-09-22 | Yeda Res & Dev | Immune cells having predefined biological specificity |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US7527787B2 (en) | 2005-10-19 | 2009-05-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
ES2321485T3 (en) | 2001-03-30 | 2009-06-08 | Leadd B.V. | FUSION PROTEINS FOR SPECIFIC TREATMENT OF CANCER AND AUTOIMMUNE DISEASES. |
CN1294148C (en) | 2001-04-11 | 2007-01-10 | 中国科学院遗传与发育生物学研究所 | Single-stranded cyctic trispecific antibody |
JP4049297B2 (en) | 2001-06-11 | 2008-02-20 | 株式会社ルネサステクノロジ | Semiconductor memory device |
US20100081792A1 (en) | 2001-06-28 | 2010-04-01 | Smithkline Beecham Corporation | Ligand |
GB0115841D0 (en) | 2001-06-28 | 2001-08-22 | Medical Res Council | Ligand |
DE60237282D1 (en) | 2001-06-28 | 2010-09-23 | Domantis Ltd | DOUBLE-SPECIFIC LIGAND AND ITS USE |
JP4213586B2 (en) | 2001-09-13 | 2009-01-21 | 株式会社抗体研究所 | Camel antibody library production method |
US20050059103A1 (en) | 2001-11-09 | 2005-03-17 | Veuskens Jacky Theo Maria | Means and methods for the detection of immunoglobulin capable of binding to mycobacterium antigen |
US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
AU2003216341A1 (en) | 2002-02-20 | 2003-09-09 | Dyax Corporation | Mhc-peptide complex binding ligands |
FR2837837B1 (en) | 2002-03-28 | 2006-09-29 | Roussy Inst Gustave | PEPTIDE EPITOPES COMMON TO ANTIGENS OF THE SAME MULTIGENIC FAMILY |
WO2003089467A1 (en) | 2002-04-19 | 2003-10-30 | Leadd B.V. | Fragments of apoptin |
ES2263984T3 (en) | 2002-06-28 | 2006-12-16 | Domantis Limited | DOUBLE-SPECIFIC LINKS WITH AN INCREASED SERIOUS MIDDLE LIFE. |
US7820166B2 (en) | 2002-10-11 | 2010-10-26 | Micromet Ag | Potent T cell modulating molecules |
AU2003286263A1 (en) | 2002-12-03 | 2004-06-23 | Avidex Ltd. | Complexes of receptors |
EP3000886A1 (en) | 2003-03-19 | 2016-03-30 | Amgen Fremont Inc. | Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof |
WO2004106380A2 (en) | 2003-05-31 | 2004-12-09 | Micromet Ag | Human-anti-human cd3 binding molecules |
US7635472B2 (en) | 2003-05-31 | 2009-12-22 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
ES2296423B1 (en) | 2003-07-31 | 2009-03-16 | Consejo Sup. Investig. Cientificas | CONSTRUCTION OF DNA FOR THE PRODUCTION OF DIMERIC FUSION PROTEINS AND ITS APPLICATIONS. |
US20050026881A1 (en) | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease |
US7488793B2 (en) | 2003-09-22 | 2009-02-10 | Ludwig Institute For Cancer Research | Isolated peptide which binds to HLA-Cw*07 and uses thereof |
DK2161283T3 (en) | 2003-11-17 | 2014-09-01 | Genentech Inc | COMPOSITIONS CONTAINING ANTIBODIES AGAINST CD79b CONJUGED TO A GROWTH INHIBITOR OR CYTOTOXIC AGENT, AND METHODS FOR TREATING TUMOR OF HEMATOPOIETIC ORIGIN |
AU2004299833B2 (en) | 2003-12-10 | 2009-05-07 | E. R. Squibb & Sons, L.L.C. | Interferon alpha antibodies and their uses |
US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
JP4658967B2 (en) | 2003-12-24 | 2011-03-23 | ジェネンテック, インコーポレイテッド | Compositions and methods for the treatment of tumors of hematopoietic origin |
US20050266425A1 (en) | 2003-12-31 | 2005-12-01 | Vaccinex, Inc. | Methods for producing and identifying multispecific antibodies |
US8143376B2 (en) | 2004-05-19 | 2012-03-27 | Immunocore Limited | High affinity NY-ESO T cell receptor |
AU2005251563B2 (en) | 2004-06-09 | 2011-08-04 | Technion Research & Development Foundation Ltd. | Antibodies for selective apoptosis of cells |
WO2006037960A2 (en) | 2004-10-01 | 2006-04-13 | Avidex Ltd. | T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents |
AU2006315580A1 (en) | 2005-11-10 | 2007-05-24 | Curagen Corporation | Method of treating ovarian and renal cancer using antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen |
CA2634292A1 (en) | 2005-12-20 | 2007-06-28 | Erasmus University Medical Center Rotterdam | Apoptosis-inducing protein complexes and therapeutic use thereof |
CA2633713A1 (en) | 2005-12-21 | 2007-06-28 | Micromet Ag | Epha2 bite molecules and uses thereof |
GB0601513D0 (en) | 2006-01-25 | 2006-03-08 | Univ Erasmus Medical Ct | Binding molecules 3 |
AT503902B1 (en) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | METHOD FOR MANIPULATING IMMUNE LOBULINS |
WO2008120202A2 (en) | 2007-03-29 | 2008-10-09 | Technion Research & Development Foundation Ltd. | Antibodies, methods and kits for diagnosing and treating melanoma |
AU2008282218A1 (en) | 2007-07-31 | 2009-02-05 | Medimmune, Llc | Multispecific epitope binding proteins and uses thereof |
ES2447844T3 (en) | 2008-04-03 | 2014-03-13 | Vib Vzw | Individual domain antibodies capable of modulating BACE1 activity |
WO2009131435A1 (en) | 2008-04-23 | 2009-10-29 | Erasmus University Medical Center Rotterdam | Linker containing bungarotoxin and a binding peptide |
BRPI0913366A8 (en) | 2008-06-03 | 2017-07-11 | Abbott Lab | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND THEIR USES |
US10981998B2 (en) | 2008-10-01 | 2021-04-20 | Amgen Research (Munich) Gmbh | Cross-species-specific single domain bispecific single chain antibody |
WO2010059315A1 (en) | 2008-11-18 | 2010-05-27 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
JP2012512646A (en) | 2008-12-19 | 2012-06-07 | アブリンクス エン.ヴェー. | Methods for generating immunoglobulin sequences |
GB0908613D0 (en) | 2009-05-20 | 2009-06-24 | Immunocore Ltd | T Cell Reseptors |
WO2010136172A1 (en) | 2009-05-27 | 2010-12-02 | F. Hoffmann-La Roche Ag | Tri- or tetraspecific antibodies |
GB0911566D0 (en) | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
WO2011063348A1 (en) | 2009-11-23 | 2011-05-26 | Amgen Inc. | Monomeric antibody fc |
WO2011064664A2 (en) | 2009-11-24 | 2011-06-03 | Chrontech Pharma Ab | T cell receptors specific for immunodominant ctl epitopes of hcv |
US20130131088A1 (en) | 2010-01-13 | 2013-05-23 | University Health Network | Treating cancer with statins and compounds having dipyridamole activity |
US20120123218A1 (en) | 2010-11-16 | 2012-05-17 | JPWaVe BV | Methods and means for clinical investigations |
CA2822938A1 (en) | 2010-12-27 | 2012-07-05 | Apo-T B.V. | A polypeptide that binds aberrant cells and induces apoptosis |
JP6177137B2 (en) | 2010-12-27 | 2017-08-09 | エーピーオー‐ティー ビー.ヴイ. | Cross-linked polypeptides that induce apoptosis |
AU2012316859A1 (en) | 2011-09-29 | 2014-04-17 | Apo-T B.V. | Multi-specific binding molecules targeting aberrant cells |
WO2013105856A1 (en) | 2012-01-13 | 2013-07-18 | Apo-T B.V. | Aberrant cell-restricted immunoglobulins provided with a toxic moiety |
AU2013281327A1 (en) | 2012-06-26 | 2015-01-22 | Apo-T B.V. | Binding molecules targeting pathogens |
-
2013
- 2013-01-11 WO PCT/NL2013/050014 patent/WO2013105856A1/en active Application Filing
- 2013-01-11 EP EP13703480.7A patent/EP2802356A1/en not_active Ceased
- 2013-01-11 US US13/739,974 patent/US20130183307A1/en not_active Abandoned
- 2013-01-11 US US14/372,094 patent/US10946104B2/en active Active
- 2013-01-11 SG SG10201705698PA patent/SG10201705698PA/en unknown
- 2013-01-11 SG SG11201404007WA patent/SG11201404007WA/en unknown
- 2013-01-11 CA CA2860914A patent/CA2860914A1/en not_active Abandoned
- 2013-01-11 JP JP2014552149A patent/JP2015504895A/en active Pending
- 2013-01-11 AU AU2013208364A patent/AU2013208364B2/en not_active Ceased
- 2013-01-11 EP EP18207894.9A patent/EP3470434A1/en not_active Withdrawn
-
2014
- 2014-07-11 ZA ZA2014/05109A patent/ZA201405109B/en unknown
-
2015
- 2015-03-26 US US14/670,271 patent/US20150202318A1/en not_active Abandoned
-
2017
- 2017-12-01 JP JP2017232042A patent/JP2018083814A/en active Pending
- 2017-12-28 US US15/857,354 patent/US20180154013A1/en not_active Abandoned
-
2018
- 2018-01-19 AU AU2018200442A patent/AU2018200442B2/en not_active Ceased
-
2019
- 2019-12-27 JP JP2019238199A patent/JP2020097579A/en active Pending
-
2021
- 2021-01-11 US US17/146,178 patent/US20210205465A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2013105856A1 (en) | 2013-07-18 |
AU2018200442B2 (en) | 2019-12-05 |
JP2020097579A (en) | 2020-06-25 |
EP3470434A1 (en) | 2019-04-17 |
US10946104B2 (en) | 2021-03-16 |
US20130183307A1 (en) | 2013-07-18 |
CA2860914A1 (en) | 2013-07-18 |
JP2018083814A (en) | 2018-05-31 |
EP2802356A1 (en) | 2014-11-19 |
AU2018200442A1 (en) | 2018-02-08 |
AU2013208364B2 (en) | 2017-10-26 |
ZA201405109B (en) | 2015-12-23 |
US20150202318A1 (en) | 2015-07-23 |
US20150056198A1 (en) | 2015-02-26 |
US20180154013A1 (en) | 2018-06-07 |
AU2013208364A1 (en) | 2014-08-07 |
SG11201404007WA (en) | 2014-08-28 |
JP2015504895A (en) | 2015-02-16 |
US20210205465A1 (en) | 2021-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201405109B (en) | Aberrant cell-restricted immunoglobulins provided with a toxic moiety | |
PT3316885T (en) | Antibody-sn-38 immunoconjugates with a cl2a linker | |
ZA201308319B (en) | A dual steerable | |
GB2499733B (en) | Routing a call | |
ZA201405490B (en) | Antiviral compounds with a heterotricycle moiety | |
GB2508701B (en) | A knee-walker | |
GB2494219B (en) | A fairing | |
GB2504847B (en) | A tubular connection | |
GB201223264D0 (en) | A hydrogen-storage-material | |
GB2520217B (en) | A spool assembly | |
HK1174193A2 (en) | A torch | |
GB201321180D0 (en) | A footgauge | |
GB2499227B (en) | A telescopic member | |
GB2495322B (en) | A Trestle Assembly | |
GB2504309B (en) | A workbench | |
GB201207514D0 (en) | A modular strimmer | |
GB2507995B (en) | A hand sanitiser | |
GB2506132B (en) | A fuseboard | |
ZA201304575B (en) | A primping accessory | |
GB2487587B (en) | A painting aid | |
GB201207460D0 (en) | A servomechanism | |
GB201216979D0 (en) | A guard | |
GB201212053D0 (en) | A tubular connection | |
ZA201305468B (en) | Connecting mechanisms for a guy-wire | |
GB201116986D0 (en) | A folding mudguard |